Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The SELECT trial, published in the New England Journal of Medicine , found that semaglutide, known by the brand name Ozempic, significantly reduced the risk of heart attacks and strokes in people with obesity and established cardiovascular disease
This study was supported by National Key R&D Program of China (2023YFC2509100), Science and Technology Commission of Shanghai Municipality (23Y31900400), National Natural Science Foundation of China (82370984 & 82370980), Natural Science Foundation of Shanghai (22ZR1437600), Shanghai's Top Priority Research Center (2022ZZ01017), and Dominant disease biological sample project of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (YBKA202201)
Sellers have attempted to take advantage of a perceived legal loophole, labelling the substances as research chemicals that are not for human consumption
doi: 10.1016/j.autrev.2009.02.020
